FDA Inspection 1116333 — Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany
The FDA completed an inspection of Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany on Dec 20, 2019 in Whippany, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Dec 20, 2019
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Whippany, NJ (United States)